SCHEMBL11029481

SCHEMBL11029481

CN1CCN(c2ccc(Nc3cc(Cc4cccc(Cl)c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.52
▸ MAPKAPK2 P49137 2/20 0.50
▸ STAT6 P42226 2/20 0.48
▸ JAK3 P52333 3/20 0.47
▸ PTK2 Q05397 2/20 0.47
▸ NTRK1 P04629 2/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ RAD52 P43351 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ MAPK14 Q16539 1/20 0.46
▸ EGFR P00533 3/20 0.46
▸ KCNQ2 O43526 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ CSF1R P07333 1/20 0.43
▸ MAP3K7 O43318 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11030519 0.90 MAPKAPK2 (0.49) SLC2A1MAPKAPK2STAT6JAK3PTK2
SCHEMBL11025349 0.90 SLC2A1 (0.52) SLC2A1MAPKAPK2STAT6JAK3JAK2
SCHEMBL11025081 0.90 STAT6 (0.55) SLC2A1MAPKAPK2STAT6PTK2EGFR
SCHEMBL11028029 0.89 CDK4 (0.53) SLC2A1MAPKAPK2STAT6JAK3PTK2
SCHEMBL11030740 0.88 SLC2A1 (0.55) SLC2A1MAPKAPK2STAT6JAK3PTK2
SCHEMBL11031933 0.88 MAPKAPK2 (0.51) SLC2A1MAPKAPK2STAT6PTK2JAK2
SCHEMBL11029790 0.87 MAPKAPK2 (0.52) SLC2A1MAPKAPK2STAT6JAK3PTK2
SCHEMBL11027886 0.86 SLC2A1 (0.47) SLC2A1MAPKAPK2STAT6JAK3PTK2
SCHEMBL11029564 0.85 TNIK (0.52) SLC2A1STAT6PTK2EGFRAURKA
SCHEMBL11033990 0.85 SLC2A1 (0.54) SLC2A1STAT6JAK3JAK2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885MAPKAPK2 115/4885STAT6 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback